Who should pay for the continuity of post-trial health care treatments?

BACKGROUND: The bioethical debate in the world on who should pay for the continuity of post-trials treatment of patients that have medical indication remains obscure and introduces uncertainties to the patients involved in the trials. The continuity of post-trial treatment was only incorporated in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Iunes, Roberto, Uribe, Manuela Villar, Torres, Janet Bonilla, Garcia, Marina Morgado, Alvares-Teodoro, Juliana, de Assis Acurcio, Francisco, Junior, Augusto Afonso Guerra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545625/
https://www.ncbi.nlm.nih.gov/pubmed/31155007
http://dx.doi.org/10.1186/s12939-019-0919-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545625/
https://www.ncbi.nlm.nih.gov/pubmed/31155007
http://dx.doi.org/10.1186/s12939-019-0919-0

Ejemplares similares